ArticleClinical rheumatology2015

Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.

Ziga Rotar et al.PubMed ↗Publisher ↗

No numbers read from the abstract.